On October 19, 2026 Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, reported the company will present promising preliminary clinical data from the ongoing Phase 1 portion of its Phase 1/2 PROSPER trial evaluating FMC-376, an equipotent KRAS G12C ON+OFF inhibitor, in patients with advanced KRAS G12C-mutant solid tumors, focused on non-small cell lung cancer (NSCLC). The findings will be presented during a rapid oral session at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27 in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract reports preliminary anti-tumor activity, including responses in patients previously treated with KRAS G12C inhibitors, alongside an encouraging tolerability profile. Presentation details are as follows:
Title: Phase 1 study of FMC-376, a KRAS G12C equipotent ON+OFF inhibitor in pts with advanced KRAS G12C mutant solid tumors
Presentation Number: 1006RO
Session Title: Rapid oral: Developmental therapeutic
Presentation Date & Time: Sunday, October 25, 8:30–8:35 a.m. CET
Location: Cordoba Auditorium – Hall 4
Presenter: Marcelo V. Negrao, M.D., Associate Professor, UT MD Anderson Cancer Center, Houston, Texas
About FMC-376
FMC-376 is a dual inhibitor of the ON+OFF states of KRAS G12C, directly targeting both the active and inactive forms of KRAS G12C with equipotency and high selectivity. This differentiated mechanism of action offers the potential to overcome the resistance and lack of response seen with current KRAS G12C single-acting treatments. The KRAS G12C mutation is most prevalent in people with non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC). FMC-376 has demonstrated robust anti-tumor activity in preclinical models and is currently being evaluated in the PROSPER Phase 1/2 clinical trial, an open-label, dose-escalation, dose-expansion and cohort-expansion study evaluating the safety, pharmacokinetics and clinical activity of FMC-376 as monotherapy or in combination with pembrolizumab in participants with KRAS G12C-mutated locally advanced unresectable or metastatic solid tumors.
(Press release, Frontier Medicines, OCT 19, 2026, View Source [SID1234673592])